SCHEMBL4722979

SCHEMBL4722979

CCN(CC)c1cccc2c1[CH]c1ccccc1-2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
TSHR P16473 2/20 0.32
ALDH1A1 P00352 3/20 0.31
MAPT P10636 1/20 0.31
CYP3A4 P08684 1/20 0.31
TP53 P04637 1/20 0.30
CYP1A2 P05177 1/20 0.30
RET P07949 1/20 0.30
CHRM2 P08172 1/20 0.30
HTR1A P08908 1/20 0.30
CYP2D6 P10635 1/20 0.30
CHRM1 P11229 1/20 0.30
DRD2 P14416 1/20 0.30
ALOX15 P16050 1/20 0.30
ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723530 0.90 CRHR1 (0.35) MEN1KMT2AGAARAB9ATSHR
SCHEMBL4721732 0.88 CRHR1 (0.39) MEN1KMT2AGAARAB9ATSHR
SCHEMBL4765912 0.86 CRHR1 (0.40) MEN1KMT2ATSHRMAPTTP53
SCHEMBL4719924 0.84 TP53 (0.33) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL4724339 0.83 CRHR1 (0.36) MEN1KMT2AALDH1A1TP53DRD3
SCHEMBL4724521 0.81 CRHR1 (0.40) MEN1KMT2AALDH1A1DRD3
SCHEMBL215956 0.79 MAPT (0.43) MEN1KMT2AGAARAB9ATSHR
SCHEMBL4721790 0.78 DRD3 (0.35) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL15400228 0.76 KDM4E (0.32) ALDH1A1MAPTCYP3A4CYP1A2CYP2D6
SCHEMBL4723422 0.76 KDM4E (0.40) MEN1KMT2ATSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MEN1 4451/4885KMT2A 3345/4885GAA 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.